Full-Time

Trial Master File

Tmf, Specialist

Posted on 1/18/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$90k - $120k/yr

Mid

San Francisco, CA, USA

Preferred candidates are based in the SF Bay Area.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in a scientific discipline or equivalent experience
  • Minimum of 3-4 years of biotech/pharmaceutical industry or contract research organization (CRO) experience
  • Knowledge of the DIA TMF Reference Model and how documents from various functional areas map and meet TMF filing requirements
  • Knowledgeable of Good Clinical Practice (GCP), and EU and FDA requirements for TMF content/structure, in relation to document quality control and review
  • Experience managing TMF documents utilizing the TMF Reference Model
  • Experience in conducting/managing TMF Quality Control activities
  • Understanding of basic personal data privacy principles, Private Health Information, HIPPA, and GDPR protections for document content during quality control reviews
  • Experience with managing large spreadsheets in MS Excel
Responsibilities
  • Support the implementation and management of record management processes related to the electronic Trial Master File (eTMF) and ensure compliance with internal policies as well as external regulations
  • With the Senior Manager, TMF Operations, serve as the operational process and subject matter representative to the clinical study team –researching and providing direction to team members on general and specific best practices in the documentation for clinical trials and presenting TMF status and expectations to the entire study team
  • Support the preparation and management of TMF Plans and Content Lists – assuring study team and vendor compliance to plan and content list language – demands attention to detail, adequate or better application awareness of MS Excel and MS Word
  • Support management of study eTMF setup, user access management, and document processing in eTMF system
  • Perform eTMF quality reviews for Sponsor Oversight; identify document deficiencies and track them to resolution or rejection
  • Maintain and report eTMF quality metrics for studies, create and edit reports and dashboards to facilitate study team awareness
  • Direct and escalate quality-related concerns in gathered documentation
  • Develop expert awareness of the filing structure and navigation of the system for continued inspection readiness and support, but also user support and education
  • Oversee TMF quality for both the QED TMF and the CRO TMF across QED trials
  • Facilitate the development and maintenance of the QED trial-specific Content Maps and Plans, Study Milestone Design and Expected Document Lists
  • Identify, Facilitate and Adjudicate discussions of QED functional area TMF content accountability
  • Facilitate QED TMF QC activities and track issues to completion
  • Coordinate with CRO and study vendors to oversee the timely completion and resolution of issues from their QC activities
  • Facilitate QED TMF system access requests/removal for team members
  • Support activities related to ongoing TMF maintenance, close-out, transfer, and archival of study TMFs
  • Support study teams during regulatory inspections and serve as subject matter expert (SME) for Regulatory Inspection activities
Desired Qualifications
  • Experience in working in CRO-owned eTMF system and User Access Management
  • Previous participation with validation of electronic document management systems / eTMFs
  • Excellent organizational skills, ability to manage multiple tasks and maintain meticulous attention to detail
  • Experience with process implementation and management principles
  • Can embrace the guiding principles of BridgeBio - #every-minute-counts, #let-science-speak, #put-patients-first, #think-independently, #radical-transparency
  • Positive, team-oriented attitude a must.

BridgeBio Pharma develops medicines for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources, which enhances efficiency. By leveraging advancements in genome sequencing and molecular biology, BridgeBio aims to create significant therapeutic advancements. Their goal is to bring new treatments to market faster through a diverse pipeline of drug programs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent approval of Beyonttra in Japan enhances BridgeBio's market presence.
  • Strategic partnerships expand BridgeBio's reach and resources in the biotech industry.
  • Advancements in AI and genetic data boost BridgeBio's R&D capabilities.

What critics are saying

  • Increased competition from Alnylam's Amvuttra may impact market share.
  • Financial risk from $500 million convertible senior notes if revenue projections fall short.
  • Reliance on Alexion for Beyonttra's commercial activity in Japan poses potential risks.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focuses on genetic diseases with well-understood genetic causes for targeted therapies.
  • Leverages genome sequencing and molecular biology for innovative treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

0%
BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

BioSpace
Mar 25th, 2025
Bridgebio To Present Cardiovascular Outcomes Data In Patients With Variant And Wild-Type Transthyretin Amyloid Cardiomyopathy (Attr-Cm) From The Attribute-Cm Study At The Acc Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.Flatboard Poster Presentations:Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid CardiomyopathyPresenter: Margot Davis, M.D. of Vancouver General Hospital, CADate: Monday, March 31 at 9:00 am CT/10:00 am ETAcoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ETIn Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsPresenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USADate: Monday, March 31 at 9:00 am CT/10:00 am ETRobustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity AnalysesPresenter: Jan Griffin, M.D

Value the Markets
Mar 24th, 2025
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis

Amvuttra will compete with Pfizer's Vyndaqel and BridgeBio's Attruby.

GlobeNewswire
Feb 26th, 2025
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced...

The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

INACTIVE